Skip to Content

Teduglutide Disease Interactions

There are 5 disease interactions with teduglutide:

Moderate

teduglutide (Includes teduglutide) ↔ intestinal obstruction

Moderate Potential Hazard, Moderate plausibility. Applies to: Intestinal Obstruction

Intestinal obstruction has been reported in clinical trials with teduglutide. In patients who develop intestinal or stomal obstruction, treatment with teduglutide should be temporarily discontinued while the patient is clinically managed. Treatment may be restarted when the obstructive episode resolves, if clinically indicated. Caution is advised in patients with risk factors for intestinal obstruction.

Moderate

Teduglutide (Includes teduglutide) ↔ biliary and pancreatic disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Cholelithiasis, Pancreatitis

Cholecystitis, cholangitis, cholelithiasis, and pancreatitis have been reported in clinical studies with teduglutide. For identification of the onset or worsening of gallbladder/biliary/pancreatic disease, patients should undergo laboratory assessment of bilirubin, alkaline phosphatase, lipase and amylase within 6 months prior to starting teduglutide, and at least every 6 months while on treatment; or more frequently if needed. If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder, biliary tract and/or pancreas is recommended; and the need for continued teduglutide treatment should be reassessed.

Moderate

Teduglutide (Includes teduglutide) ↔ congestive heart failure

Moderate Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease, Fluid Retention

Fluid overload and congestive heart failure have been observed in clinical trials with teduglutide. This was probably related to enhanced fluid absorption associated with the medication. If fluid overload occurs, parenteral support should be adjusted and treatment should be reassessed, especially in patients with underlying cardiovascular disease. If significant cardiac deterioration develops while on teduglutide, the need to continue treatment should be reassessed.

Moderate

Teduglutide (Includes teduglutide) ↔ liver impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Teduglutide pharmacokinetics has not been assessed in patients with severe hepatic impairment. Caution and monitoring is advised. Patients with moderate hepatic impairment showed lower Cmax and AUC when compared to healthy matched control subjects after a single subcutaneous dose of teduglutide. However, no dose adjustment is necessary for patients with mild and moderate liver impairment.

Moderate

Teduglutide (Includes teduglutide) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Teduglutide is primarily cleared by the kidney and caution is advised when using in patients with moderate to severe renal impairment. The manufacturers recommend to reduced the dose by 50% in patients with moderate and severe renal impairment (creatinine clearance less than 50 mL/min), and end-stage renal disease.

Teduglutide drug interactions

There is 1 drug interaction with teduglutide

Teduglutide alcohol/food interactions

There is 1 alcohol/food interaction with teduglutide

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide